The latest announcement is out from Haleon PLC Sponsored ADR ( (HLN) ).
Haleon PLC, a company involved in consumer healthcare, announced its unaudited full-year results for 2024, revealing a slight decline in reported revenue by 0.6% to £11,233 million. Despite this, the company achieved a 5.0% organic revenue growth, driven by a combination of price increases and volume/mix improvements. The company reported a 10.5% increase in operating profit to £2,206 million, supported by restructuring efforts and divestments, including the sale of its Nicotine Replacement Therapy business outside the US. Haleon also announced a proposed 10% increase in its total full-year dividend, reflecting confidence in its financial performance and future growth prospects.
More about Haleon PLC Sponsored ADR
YTD Price Performance: 8.05%
Average Trading Volume: 8,940,503
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $45.35B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.